Biodexa Pharmaceuticals (NASDAQ: BDRX)

Last close As at 19/04/2024


−0.03 (−3.53%)

Market capitalisation


Biodexa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on oncology and rare/orphan indications. MTX110 is in Phase I clinical studies in aggressive rare/orphan brain cancer indications and tolimidone is due to start Phase I trials in type I diabetes in Q124. The preclinical pipeline includes MTD217, targeting leptomeningeal disease.

The brain cancer space comes with a high risk-reward trade off, although successful therapeutics stand to benefit materially given the unmet need. The glioblastoma therapeutics market is a $3–5bn opportunity with only a handful of drugs approved, highlighting the potential for novel therapeutics.

Latest Insights

View More
Midatech Pharma_resized



Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh


Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Dr Stephen Parker


  • Stephen Stamp

    CEO and CFO

Balance Sheet

Forecast net debt (£m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual (28.1) (57.9) (96.4)
Relative (26.1) (59.9) (97.0)
52 week high/low US$22.7/US$0.8


Following a strategic pivot in early-2023, Biodexa is now positioned as a therapeutics company with a focus on disease areas with unmet need. The current pipeline focus is on the legacy Phase I asset, MTX110, currently undergoing clinical studies in aggressive brain cancers such as glioblastoma (Phase Ib trial ongoing; progression free survival data expected in Q224) with plans for an Investigational New Drug application in diffuse midline gliomas in Q324. The preclinical program includes MTD217, targeting leptomeningeal disease, a secondary central nervous system cancer with poor prognosis. To bolster its pipeline further, Biodexa completed the acquisition of a novel lyn kinase activator, tolimidone in December 2023 with plans to develop it for type I diabetes. H123 ended with a £5.23m cash balance, bolstered further by a $6m equity raise in December 2023.

Y/E Dec Revenue (£m) EBITDA (£m) PBT (£m) EPS (p) P/E (x) P/CF (x)
2021A 0.6 (6.6) (6.1) (6.78) N/A N/A
2022A 0.7 (8.6) (8.5) (1.55) N/A N/A
2023E N/A N/A N/A N/A N/A N/A
2024E N/A N/A N/A N/A N/A N/A


Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free